Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery
Sponsor: University of Ioannina
Summary
Tranexamic axid is routinely used as an antifibrinolytic agent in cardiac surgery to reduce the risk of blood loss and transfusion. However, there is no consensus regarding the dosage regimen of tranexamic acid that should be administered. The purpose of this study is to compare different dosages of tranexamic acid in cardiac surgery using cardiopulmonary bypass regarding the duration of inhibition of fibrinolysis as measured by the ClotPro test. Blood samples will be taken from the arterial line placed in the patient at specified time points in order to perform viscoelastic tests (ClotPro, TPA test), to detect successful inhibition of fibrinolysis and to measure tranexamic acid levels in the patient's blood. In case the action of tranexamic acid stops early postoperatively an additional dose of the medication will be administered to the patient.
Official title: Comparative Study of Tranexamic Acid Dosage Regimens in Patients Undergoing Cardiac Surgery Under Cardiopulmonary Bypass
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2024-05-14
Completion Date
2027-12-15
Last Updated
2025-09-10
Healthy Volunteers
No
Conditions
Interventions
Tranexamic acid at a dose of 10 mg/kg followed by 1 mg/kg/h
Group 1: administration of tranexamic acid at a dose of 10 mg/kg followed by 1 mg/kg/h
Tranexamic acid at a dose of 20 mg/kg
Group 2: administration of tranexamic acid at a dose of 20 mg/kg
Tranexamic acid at a dose of 30 mg/kg
Group 3: administration of tranexamic acid at a dose of 30 mg/kg
Locations (1)
University Hospital of Ioannina
Ioannina, Greece